Get the Facts and Tools You Need to Help Support Your Patients Receiving DARZALEX®

Share

DARZALEX® (daratumumab)
Redefining approaches in early lines of multiple myeloma

DARZALEX® + Rd — for a strong start to their treatment journey

DARZALEX® in combination with Rd was proven effective in a clinical study of adult patients with newly diagnosed, transplant-ineligible multiple myeloma.1*

DARZALEX® may help your patients live longer without their disease getting worse1*

% of patients with progression-free survival (PFS)

More patients treated with DARZALEX® + Rd were progression-free vs Rd alone (at median follow-up of 28 months): 74% vs 61%.

  • DARZALEX® + Rd increased the time patients lived without their multiple myeloma getting worse1

In the MAIA trial, there was a demonstrated improvement in PFS in the DRd arm compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (hazard ratio [HR]=0.56; 95% CI, 0.43–0.73; P<0.0001), representing a 44% reduction in the risk of disease progression or death in patients treated with DRd.1

DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); MM=multiple myeloma; Rd=lenalidomide (R) + dexamethasone (d).

More patients responded to DARZALEX® + Rd vs Rd alone1

Overall response rates (ORRs)

More patients responded to DARZALEX® + Rd vs Rd alone: 93% vs 81%.

  • DARZALEX® + Rd nearly doubled the number of patients who achieved CR or better vs Rd alone1
    • More than doubled sCR: 30% with DRd vs 13% with Rd alone

CR=complete response; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

sCR is CR plus the attainment of normal free light-chain ratio and the absence of clonal cells in bone marrow by immunochemistry or immunofluorescence.2

Learn how to talk with patients about the MAIA trial efficacy findings.

Study Design1: MAIA, an open-label, randomized, phase 3 study, compared treatment with DARZALEX® + Rd (n=368) to Rd (n=369) in adult patients with newly diagnosed, transplant-ineligible multiple myeloma. Treatment was continued until disease progression or unacceptable toxicity. The primary efficacy endpoint was PFS.

Daratumumab (DARZALEX®) in combination with lenalidomide and dexamethasone is recommended by the NCCN® Guidelines as a preferred Category 1§ therapeutic option for non-transplant candidatesII

§Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.

IIReferenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma V.1.2020. © National Comprehensive Cancer Network, Inc. 2019. Accessed September 11, 2019. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

DARZALEX® has a demonstrated safety profile1

  • The most frequent (≥20%) adverse reactions were infusion reactions, diarrhea, constipation, nausea, peripheral edema, fatigue, back pain, asthenia, pyrexia, upper respiratory tract infection, bronchitis, pneumonia, decreased appetite, muscle spasms, peripheral sensory neuropathy, dyspnea, and cough
  • Serious adverse reactions with a 2% greater incidence in the DRd arm compared to the Rd arm were pneumonia (DRd 15% vs Rd 8%), bronchitis (DRd 4% vs Rd 2%) and dehydration (DRd 2% vs Rd <1%)